Comparison of early effects of PCV7, PCV10 and PCV13 on S. pneumoniae (SP) nasopharyngeal carriage in a population based study; the Palestinian-Israeli Collaborative Research (PICR)
R. Abu Seir, K. Azmi, A. Hamdan, H. Namouz, F. Jaar, H. Jaber, C. Rubin, D. Doron, G. Rahav, Z. Abdeen, G. Regev-Yochay
Abstract
BackgroundPneumococcal conjugate vaccines (PCVs), PCV10 and PCV13, are currently used in different countries. We have previously reported the effectiveness of PCV7, following its introduction in Israel and before PCVs were introduced in Palestine. Here, we extended the study and compared the initial impact of PCV10 to that of PCV7/13.\n\nMethodsFour cross-sectional surveys of S. pneumoniae carriage among children <5y through 2009-2014 were preformed among two proximate populations, living under two distinct health authorities, with different vaccination policies. In East-Jerusalem (EJ), PCV7 was implemented in 2009 and replaced by PCV13 in late 2010, while in Palestine (PA), PCV10 was implemented in 2011.\n\nResultsA total of 1267 and 2414 children from EJ and PA were screened. Implementation of both PCV7 (in EJ) and PCV10 (in PA) did not affect overall S. pneumoniae carriage ([~]30%), but resulted in a significant decrease in carriage of VT7 strains. In the pre-vaccine era, VT7/VT13 strains consisted 47.0%/62.0% and 41.2%/54.8% of pneumococci in EJ and PA, respectively. A 48.6% and 53.9% decrease was observed within 3 years of PCV7 implementation in EJ (p= 0.001) and PCV10 in PA (p<0.0001), respectively. These vaccination policies also resulted in [~]50% reduction in VT13-added serotypes especially 6A (from 11.0% to 0.0% (EJ) and 9.5% to 4.9% (PA)). Three years after PCV13 implementation in EJ, an additional 67% decrease in VT13 strains was observed, yet an increase in serotype 3 was observed (0.0% to 3.4%, p=0.056). The prevalence of non-VT13 strains increased during the study period from 38% and 45.3% to 89.8% and 70.7%, in EJ and in PA respectively.\n\nConclusionsWithin the first three years following PCV implementation, we observed similar reductions in carriage of VT10 and VT13 strains with either vaccination policies, with no effect on overall carriage. Further follow-up is needed to compare the long-term effects.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Early signals of vaccine driven perturbation seen in pneumococcal carriage population genomic data
Chrispin Chaguza, Ellen Heinsbroek, … Stephen D. Bentley·Clinical Infectious DiseasesPeer-reviewed·May 15, 2019
- Population genomics of pneumococcal carriage in Massachusetts children following PCV-13 introduction
P. Mitchell, T. Azarian, … W. Hanage·Microbial GenomicsPeer-reviewed·Feb 1, 2019
- Efficacy of PCV vaccine is primarily mediated by controlling pneumococcal colonisation density
E.L. German, C. Solórzano, … D.M. Ferreira·bioRxiv·Feb 14, 2019
- Therapeutic immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density, shedding, and middle ear infection in mice
J. Manning, S. Manna, … C. Satzke·bioRxiv·Apr 5, 2023
- Estimating the impact of pneumococcal conjugate vaccines on childhood pneumonia in sub-Saharan Africa: A systematic review.
C. Onwuchekwa, B. Edem, … E. oga·F1000ResearchPeer-reviewed·Jul 23, 2020
- Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae
D. W. Cleary, V. T. Devine, … S. C. Clarke·bioRxiv·Dec 4, 2017